Vasomune Therapeutics, Inc.
Vasomune Therapeutics is a private clinical-stage biopharmaceutical company focused on developing novel therapeutics for diseases associated with vascular dysfunction. Their lead drug candidate, Pegevongitide (AV-001), enhances the body's ability to reverse vascular endothelial instability and vascular leak, particularly in conditions such as Acute Respiratory Distress Syndrome (ARDS), hemorrhage, and following toxin exposure.
Vasomune Therapeutics, Inc.
180 John Street, Suite 305, Toronto, ON M5T 1X5
Patents
Agent for promoting angiogenesis and methods and uses thereof
2022-07-12 • US-11384130-B2
View DetailsWhat We Do
Pegevongitide (AV-001) is a first-in-class synthetic Angiopoietin 1 mimetic designed to activate the Tie2 receptor, promoting vascular stability and counteracting vascular leak. It is being developed for the treatment of pathogen-induced Acute Respiratory Distress Syndrome (ARDS) and other conditions associated with vascular dysfunction and leak.
Regenerative Medicine
Application Area
Show More (2)Drugs
Key People
President & COO
Vice-President, Research & Scientific Affairs
Vice-President, Finance
Vice-President, Operations & Planning
News & Updates
Vasomune Therapeutics has received Fast Track Designation from the US FDA for AV-001, a novel investigational medicine.
Vasomune Therapeutics has been selected to present its lead drug candidate AV-001 at the 2024 Respiratory Innovation Summit.
Vasomune and AnGes announced that AV-001 received a positive recommendation from the IDSMB for the Phase 2a study.